Chemical and Biochemical Characterisation of Novel Iron Chelators with Therapeutic Potential

具有治疗潜力的新型铁螯合剂的化学和生化表征

• 批准号: DP0773027
• 负责人: Prof Paul Bernhardt
• 金额: $ 42.7万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-12-01 至 2010-03-31
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0773027
• 关键词: Chemical; Biochemical; Characterisation; Novel; Iron

Resistance by cancers to established chemotherapeutics is a growing problem in the community and one that demands the development of new strategies. Chelators that target the essential element iron within cancer cells represent a novel and promising approach to this problem. The Chief Investigators represent a unique combination of expertise in coordination chemistry and the biochemistry of iron chelation. They have discovered and characterised new chelators that show marked anticancer activity, and act by a new mechanism that overcomes problems of resistance. In this project they will pursue a course that will lead to a greater understanding of how these compounds work with the outcome that new effective anticancer drugs may emerge.

癌症对现有化疗药物的耐药性是一个日益严重的问题，需要开发新的治疗策略。靶向癌细胞内必需元素铁的螯合剂代表了解决这一问题的一种新颖而有前途的方法。首席研究员代表了在配位化学和铁螯合生物化学方面的专业知识的独特组合。他们发现并描述了新的螯合剂，这些螯合剂显示出明显的抗癌活性，并通过一种克服耐药性问题的新机制起作用。在这个项目中，他们将学习一门课程，以更好地了解这些化合物是如何与可能出现的新的有效抗癌药物的结果一起工作的。